Figure 1. AZ58 overcomes resistance to gemcitabine and cisplatin in select urothelial cancer cell lines. Ten urothelial cancer cell lines were exposed to 1 μM each of gemcitabine and cisplatin for 48 h. Cells were harvested for PI-FACS analysis. Asterisks indicate cell lines sensitive to the drug combination (30% DNA fragmentation). Error bars = standard error. The same 10 urothelial cancer cell lines were exposed to AZ58 at 30 nM in addition to gemcitabine and cisplatin. Double asterisks indicate cell lines sensitive to the drug combination (30% DNA fragmentation).